The defi nition of osteoporosis was originally formulated at a conference of the World Health Organization (WHO) in 1993 as 'a systemic skeletal disease characterized by decreased bone mass and altered micro-architecture of bone tissue, leading to enhanced bone fragility and risk of fractures'. Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural and bio-mechanical properties that are required to maintain bone homeostasis. This review aims to address the currently available options in prevention and treatment of osteoporosis. Management of osteoporosis includes non-pharmacological treatment -diet rich of calcium and vitamin D, healthy lifestyle, proper exercise plan, and pharmacological therapy. Combination of non-pharmacological and pharmacological treatment options have to be considered for prevention of osteoporosis and minimization of the risk of fractures. Given the heterogeneity of osteoporosis syndrome and lack of signifi cant number of comparative studies, the choice of a pharmacological agents should be individualized. : osteoporosis, treatment, prevention, pharmacology, structure-activity Folia Medica 2015;57(3&4):181-190 Copyright © 2015 Medical University, Plovdiv РЕЗЮМЕ Определение остеопороза первоначально сформулировано на конференции Всемирной организации здравоохранения (ВОЗ) в 1993 г. как: "системное заболевание скелета, которое характеризуется снижением костной массы, нарушением микроархитектоники костной ткани, усилением хрупкости кости и повышением риска переломов". Остеопороз характеризуется снижением плотности костей (bone mineral density -BMD) и потерей структурных и биохимических свойств, необходимых для поддерживания гомеостаза костей. Целью настоящего обзора является выяснение наличных на данный момент возможностей профилактики и лечения остеопороза. Терапия остеопороза включает нефармакологические методы -диета, обеспечивающая поступление в организм кальция и витамина Д, здоровый образ жизни, подходящий режим физических нагрузок, а также фармакологическую терапию. Комбинация нефармакологических и фармакологических методов терапии должна быть тщательно продуманной с целью профилактики остеопороза и понижения риска переломов. Учитывая гетерогенность синдрома остеопороза и отсутствие значительного количества сравнительных исследований, выбор фармакологических агентов должен быть строго индивидуализирован.
INTRODUCTION
The defi nition of osteoporosis was originally formulated at a conference of the World Health Organization (WHO) in 1993 as a systemic skeletal disease characterized by decreased bone mass and altered microarchitecture of bone tissue 1 , leading to enhanced bone fragility and risk of fractures'. 2 Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural and biomechanical properties that are required to maintain bone homeostasis. In 2001, at a conference of the American Institute of Health osteoporosis was defi ned as "bone damage, characterized by compromised bone strength (bone density and quality of bone tissue), predisposing the individual to an increased risk of fractures occurring spontaneously or after minor injuries. Fractures due to bone fragility result from osteoporosis, affecting most often the spine, hip and forearm. 3 The imbalance between the activity of osteoblast and osteoclast is the major cause of osteoporosis. 4 
CLASSIFICATION OF TYPES OF OSTEOPOROSIS
Osteoporosis can be primary and secondary. Primary osteoporosis: 1) postmenopausal (type 1) 5 -is typical for women between 45 and 65, due mainly to the loss of ovarian function and estrogen defi ciency and mainly affecting the vertebral bodies -trabecular bone 6 ; 2) senile (type 2) -in women over 70-75, and is pre-determined by decreased intake of calcium and vitamin D, decreased intestinal absorption, reduced production and metabolism of vitamin D in the body and the aging process; 3) idiopathic (juvenile) fractures -a rare form: for individuals in fertile age (under 40) 7 .
Secondary osteoporosis is induced by diseases or medications affecting bone tissue 8 . Long-term administration of glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, androgen deprivation therapy, thiazolidinedione, heparin, calcineurin inhibitors, and some chemotherapies such as methotrexate have deleterious effects on bone health. 8, 9 An important secondary type is a glucocorticoid-induced osteoporosis, which develops very quickly. 10 The degree of bone loss 10-40% occurs during the fi rst year of corticosteroids therapy. Risk factors are: high cumulative dose and prolonged duration of glucocorticoid therapy; age above 50 years, postmenopausal status, diseases accompanied by increased production of interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) (rheumatoid arthritis). 8 Osteoporosis occurs in 50% of patients treated with glucocorticoids for more than 6 months and fractures occur in 1/3 of patients within the fi rst 6 to 12 months. 11 The mechanisms of corticosteroids affecting the bone health are: 1) reducing the intestinal absorption of calcium which leads to increased bone resorption; 2) directly inhibiting osteoblasts function by: suppression of growth factors: BMP-2 (bone morphogenetic protein-2) and 1-C bfα (binding factor α1), reduction of IGFs (insulin-like growth factor), inhibition of proliferation and differentiation of pre-osteoblasts, promoting their differentiation to adipocytes and potentiation of apoptosis of mature osteoblasts and osteocytes; 3) directly stimulating bone resorption; 4) decreased circulating levels of sex hormones and may cause necrosis of the hip 10, 11 .
EPIDEMIOLOGY
Osteoporosis is estimated to affect 200 million people and in 2000 it was designated as the third socially signifi cant diseases in the world (after cardiovascular and oncological diseases), forecast to take second place by 2020. 3 Due to its high prevalence throughout the world, it is considered a major risk factor for public health. Bone resorption is a natural phenomenon and can occur due to old age. 12 Osteoporosis affects men and women of any age, more commonly postmenopausal women [12] [13] [14] and women over 50 years of age 5 . Osteoporosis is more common in women than in men: 50% of women 14 and 25% of men aged over 50 have osteoporotic fractures 15 . The risk of fracture increases steadily with age in both sexes and is associated with reduced bone mineral density. 16 After 50 years of age one in three women and one in fi ve men can get at least one fracture due to bone fragility. 17 The risk of fractures in women aged over 50 is 53.2% and for men is 20.7%. 18 The risk after 50 for women (53.2%) is greater than the corresponding risk of endometrial carcinoma (2.6%), breast cancer (10%), stroke (20%), and coronary heart disease (46%). 16 
ETIOLOGY
Risk factors for the disease are controllable and uncontrollable 16 .
Uncontrollable factors include: age over 65 years, sex, race, genetic factors, familial predisposition, previous fractures, insuffi cient bone growth, oxidative stress, premature menopause, diseases, medications. 12, 16, 18 Diseases that are a risk factor for secondary osteoporosis are: 1) gastrointestinal: gastrectomy, infl ammatory bowel disease, colitis, gastric bypass, eating disorders; 2) endocrine: acromegaly, diabetes, thyrotoxicosis, Cushing syndrome, hyperparathyroidism, hypogonadism; 3) hematologic disorders: leukemia, lymphoma, multiple myeloma, sickle cell anemia, thalassemia, hemophilia; 4) other diseases: ankylosing spondylitis, asthma, renal insuffi ciency, spinal damage, stroke, ischemic heart disease, systemic lupus erythematosus, induced menopause, multiple sclerosis, Alzheimer`s disease, Parkinson`s, prostate cancer, rheumatoid arthritis, 12 ; excessive use of alcohol 22 , caffeine 23 , sodium, smoking 24 ; environmental pollutants and heavy metals; lack of physical activity [25] [26] [27] [28] . Vitamins B6, C and K are important for the synthesis of bone proteins. 20 Magnesium enhances calcium absorption and transport. Zinc stimulates bone formation and inhibits bone loss. Strontium promotes differentiation of osteoblasts and helps to balance the activity of osteoclasts and osteoblasts. 3 High intake of caffeine, salt, and soda is associated with bone loss and osteoporotic fractures, due to an increased excretion of calcium in urine. 23 Chronic alcohol consumption decreases bone mass and increases the risk of fractures, slowing the proliferation and activity of osteoblasts, lowers serum osteocalcin, leads to hypogonadism, metabolic acidosis, liver disease and hypovitaminosis D, pseudo-Cushing syndrome with hipercortisolemia. 22 Smoking is connected by 1.25-fold increased total fracture risk, reduced intestinal absorption of calcium and increased metabolism of endogenous and exogenous estrogens to inactive derivatives. 25 Recent studies suggest potential role of physical exercises in prevention and management of osteoporosis. [25] [26] [27] [28] Weight-lifting exercise is associated with increases in bone density. Krasnova et al report that regular sport activities provided good prophylaxis for osteoporosis within women. 25 
PATHOGENESIS
Osteoporosis is a result of an imbalance between the activity of osteoblast and osteoclasts. 1, 2, 29 The imbalance between bone resorption and formation is attributed to extension of the life of the osteoclasts and shortening of the life of osteoblasts. 30 Remodeling of the bone in order to maintain optimal endurance consists of 4 cycles lasting several months. In the resting phase stem cells from the bone marrow migrate to the bone surface and the osteoclasts differentiate, which, during the phase of resorption creates a low pH and proteolytic enzymes are produced. During the recovery phase osteoclasts degrade the bone wound and on the bone surface attracts mesenchymal stem cells, which are transformed into osteoblasts. In the formation phase the osteoblasts form new bone through the deposition of protein matrix (osteoid consisting of collagen type I), which is mineralized. 2, 30 The activity of osteoblasts and osteoclast is under the infl uence of many regulating factorssex hormones -mainly estrogens, glucocorticoids, parathormone, calcitonin, vitamin D, RANKL. 1, 4, 7 During menopause, the rate of bone resorption is sharply increased. This increased activity of osteoblasts and osteoclasts is mainly associated with estradiol defi ciency and an increased concentration of glucocorticoids. 29 The loss of sexual hormones regulate osteoclast formation and bone marrow osteoblasts by influencing the production of interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor α (TNFα) and macrophage colony stimulating factor (M-CSF), which mediate the genesis of osteoclasts and osteoblasts. 31, 32 Osteoblast differentiation factors requires alkaline phosphatase, osteocalcin, and osteopretegrin transcription factor 2. Adipocytes are secretory cells of the bone marrow stroma that affect the osteogenesis by interfering with the osteoblast proliferation, differentiation and mineralization and enhance osteoclast formation 29 . Free radicals are responsible for the induction of apoptosis and inhibition of osteoblast genesis and activation of osteoclasts differentiation. Therefore, application of antioxidants may have a beneficial effect on bone tissue. 33 The main cause of osteoporosis in women is reduced levels of estrogen, which in postmenopausal women are one-tenth of the levels in premenopausal women. The reduced levels of estrogen leads to: 1) increase of oxidative stress; 2) apoptosis of osteoblasts; 3) rapid loss of bone mass due to an increased rate of degradation of the bone tissue by osteoclasts. 34 
DIAGNOSIS OF OSTEOPOROSIS
According to the requirements of the World Health Organization from 1994 diagnosis of osteoporosis is based on the measurement of bone mineral density (BMD), which is a quantitative criterion, refl ecting the contribution of bone changes to the overall fracture risk and a comparison of BMD of patients with the BMD of healthy young adult (between 20 and 40 years of age) of the same sex and race. 31 Determination of "T-score" represents the number of standard deviations (SD) above or below the mean BMD for the healthy young population. WHO and the International Foundation for Osteoporosis defi ned diagnostic categories: 1) healthy subjects: T > 1 SD; 2) reduced BMD (osteopenia) > 2.5 and ≤ 1 SD; 3) osteoporosis: ≤ 2.5 SD; 4) aggravated osteoporosis -in postmenopausal women and men over 50 with fractures of the hip, spine or forearm. 32 However, BMD alone has a limited value to predict the risk of fractures. The incidence of osteoporotic fractures increases with age. The predictive value of BMD becomes weaker with age. It has become evident that fracture risk is also driven by parameters including bone size and shape, bone turnover, micro-architecture, damage accumulation (micro cracks), and degree of mineralisation or collagen structure, all playing a role in bone strength, and hence in the risk of osteoporotic fractures. Several epidemiological studies showed that a large proportion of incident fragility fractures occur in postmenopausal women who have a BMD T-score above -2.5. The use of bone-related independent risk factors for fractures combined with BMD values provides a global assessment of future fracture risk, allowing the identifi cation of women who should benefi t from a treatment to prevent the occurrence of osteoporotic fractures.
The range of tests for the diagnosis of osteoporosis depends on the severity of the disease, age, presence or absence of fractures. The application of various techniques for diagnosis helps in prediction of fracture risk, tracking of age-related changes in BMD and treatment. 31, 32 TREATMENT OF OSTEOPOROSIS Goals of treatment are to reduce the incidence of new fractures and infl uence of risk factors. Most pharmacological agents used in the prevention and treatment of osteoporosis reduce bone resorption or delay the total rate of bone turnover.
INHIBITORS OF BONE RESORPTION
Bone resorption could be inhibited by: 1) reducing the formation of osteoclasts; 2) inhibition of the activity of mature osteoclasts; 3) induction of apoptosis of osteoclasts. The maturation of osteoclasts slows down as a results from intake of calcium, vitamin D, bisphosphonates, inhibitors of RANKL (denosumab), estrogens, selective estrogen receptor modulators (SERM). 1, 4, 5 . Inhibitors of the activity of mature osteoclasts are: bisphosphonates, calcitonin, cathepsin K, the protease inhibitor odanacatib. Stimulators of apoptosis of osteoclasts are bisphosphonates and calcitonin.
CALCIUM AND VITAMIN D Fundamental principle in the prevention of osteoporosis is a change in lifestyle to reduce the impact of modifi able risk factors and enhance protective factors: nutrition and physical activity [25] [26] [27] [28] . Adequate intake of inhibitors of bone resorption such as calcium, Vitamin D and combination of them is essential for preventing osteoporosis and is an essential addition to the preventive therapy 35 . Defi ciency of calcium reduces bone strength and increases susceptibility to fractures 4 . Low intake of calcium occurs with aging or in young individuals with eating disorders. The intestinal calcium absorption is decreased in patients with gastrointestinal disorders (gastrectomy, gastric bypass, pernicious anemia eating disorders), and in the elderly. 35 The recommended calcium intake with food is: a) 4-8 years -800 mg / day; b) 9-18 years -1300 mg / day; c) pre-menopausal women -1000 mg / day; d) men after teenage and until the age of 50 -1000 mg / day; e) menopausal women: 1500 mg / day; f) men over the age of 50 -1500 mg / day; g) during pregnancy and lactation -1000 mg / day. Calcium intake up to 2500 mg / day do no increases the risk for the occurrence of hypercalciuria or nephrolithiasis. Individuals with impaired kidney function should avoid excessive intake of calcium (over 2500 mg / day). 35 Hypovitaminosis D is a result from the low dietary intake, low exposure to sunlight, increased pigmentation of the skin, liver disease, obesity, or use of drugs which affect the metabolism of vitamin D, as anticonvulsants. 36, 37 Vitamin D increases bone mineral density and reduces fractures, especially when combined with an adequate intake of calcium. 35 Vitamin D3 at a daily dose of 800 IU with calcium (1000 mg) reduces the risk fractures in elderly. 2, 4, 12, [35] [36] [37] The recommended daily intake of vitamin D from food and supplements together: a) men and women in‚ 65 -≥ 600 IU (15 μg) per day; b) men and women over 65 years of age: ≥ 800 IU (20 μg) per day; in men and women with proven defi cit and during pregnancy 2000-4000 IU (50-100 μg) per day. All patients with osteoporosis undergoing anti-osteoporosis treatment, must receive a minimum of 800 IU of vitamin D per day, in order to ensure an optimal effect of the treatment. At doses of 700-1000 IU improves muscle strength and reduces fractures. 37 of an oxygen atom. P-C-P bond enhances the sustainability of enzymatic and chemical hydrolysis. The mechanism of action of bisphosphonates on bone is complex and involves a decrease in the production and activity of osteoclasts, increasing osteoclast apoptosis, resulting in specifi c inhibition of farnesyl pyrophosphate synthase, an enzyme that regulates the biosynthesis of mevalonate, cholesterol, and regulatory proteins (rab, rho , rac), that mediate osteoclast activity. 38 Bisphosphonates are used to treat metabolic bone diseases characterized by increased bone resorption: osteoporosis, Paget's disease and myeloma. 1, 4 Biphosphonates have been conclusively shown to increase bone density and reduce fractures over at least 5 years when used continuously. [5] [6] [7] Bisphosphonates inhibit bone resorption through their infl uence on the osteoclasts and decrease the risk of vertebral and non-vertebral fracture. In patients over 60-65 years of age combined intake with vitamin D and calcium preparations is required. Alendronate, and zolendronate are applied in glucocorticoid-induced osteoporosis. 38 There are two classes of bisphosphonates: the N-containing and non-N-containing bisphosphonates. The differences in the chemical structures of the two classes represent the differences in their mechanism of action. Non-N-bisphosphonates: etidronate, clodrante, tiludronate (Table 1) are metabolized in the cell to compounds which replace part of the terminal pyrophosphate adenosine triphosphate (ATP) to form non-functional molecules that compete with ATP. The N-containing bisphosphonates: neridronate, pamidronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate (Table 1) are acting on bone metabolism by binding to and blocking the enzyme farnesyl diphosphate synthase (FPP) in the path of the HMG-CoA (mevalonate pathway) resulting in preventing the formation of farnesol. 39, 40 Through clinical trials, effi cacy was demonstrated against fractures of ibandronate (MOBILE, VIBE), risedronate (VERT), zoledronate (HORIZON). Bisphosphonates effi cacy in inhibiting bone resorption is signifi cant. Connecting degree of non-containing N is: tiludronate > clodronate > etidronate, and of N-containing is: zoledronate > alendronate > ibandronate > risedronate 39 . Bonding extent explains the duration of action of zoledronate and alendronate in comparison with the more readily reversible effects of risedronate. 39, 40 INHIBITORS OF RANK-LIGAND Anti-resorptive agent denosumab is a human monoclonal antibody, which is administered subcutaneously at a dose of 60 mg 1 time per 6 months. This agent blocks the RANK/RANKL/OPG system, which is responsible for osteoclastic activation, thus reducing bone resorption. 41 Naturally RANKL is molecule produced by osteoblasts. It stimulates osteoclastogenesis via RANK, the receptor for RANKL that is present on osteoclasts. Denosumab inhibits osteoclast formation and activity. 1, 2, 4 It is at least as effective as the potent bisphosphonates in inhibiting bone resorption and has recently been approved for treatment of postmenopausal osteoporosis and some cancers (prostate and breast). The latter application is to limit the development of bone metastases or bone loss resulting from the use of drugs suppressing gonadal function. Denosumab is administered subcutaneously every 6 months, which avoids gastrointestinal side effects. The drug appears to be well tolerated. In the FREEDOM study has been found that the drug reduces vertebral fractures by 68%, non-vertebral -20%, femoral -40%. In studies, DECIDE and STAND demonstrate that denosumab increases bone density stronger than alendronate. 41 
BISPHOSPHONATES

HORMONE REPLACEMENT THERAPY (HRT)
The term "hormone replacement therapy" (HRT) is used to indicate the common use of estrogen and progestin in postmenopausal women. Until 2002 HRT has been seen as a fi rst line therapy for the prevention and treatment of postmenopausal osteoporosis. 42 Hormone replacement therapy has benefi cial effects on vertebral and non-vertebral fractures, but is not recommended as a primary indication for prevention and treatment of osteoporosis due to unfavorable risk / benefi t ratio in accordance with data from the Women's Health Initiative Study indicating increased risk of heart attack, stroke and breast cancer. 43 Hormone replacement therapy is allowed up to 3 years and at the lowest therapeutic dose (mainly as skin patches) when the expression of heavy menopausal symptoms and osteoporosis is combined. 43, 44 Hormonal therapy reduces the risk of osteoporotic fractures, improves bone mineral density (BMD), suppresses biochemical markers of bone resorption, and reduces the loss of bone mass. 1, 3, 4, 42 The mechanism of action of estrogens differs from that of bisphosphonates. The combination of these two groups of agents has additive effects on the reduction of bone resorption markers and BMD. 43, 44 Estradiol is an agonist of nuclear steroid estrogen (ER) receptors: ERα and ERβ and intracellular membrane non-nuclear estrogen receptor GPER and inhibits bone resorption. 42 In osteoporosis Estradiol could be administered also transdermally. 1, 4, 5 Progestins with stronger androgenic and weaker glucocorticoid effect (noresthisterone acetate) prevents bone loss in higher degree compared to progestins with weaker androgenic and stronger glucocorticoid action. 43 The synthetic steroid tibolone has weak estrogenic, progestogenic and androgenic properties and prevent postmenopausal bone loss. 44 In LIFT clinical study was found that tibolone signifi cantly reduces vertebral and non-vertebral fractures. 44 Effects of testosterone is effected by the activation of androgen receptors, and by conversion into estradiol. In males with hypogonadism treated with depo-testosterone 200 mg intramuscular injection bone resorption is reduced. 45 Anabolic steroids are analogs of Testosteron: 17-β-esterifi ed derivatives -Nandrolone is administered parenterally, and 17-α-methylated steroids -danazol, oxandrolone, stanozolol -orally. Anabolic steroids reduce the risk of fracture by: 1) improving calcium balance; 2) increasing the number of the osteoblasts` precursors and stimulate their differentiation into mature osteoblasts; 4) increase in the bone mineral density and recovery of skeletal microarchitecture; 5) inhibition of bone resorption. 45 
CALCITONIN
Calcitonin is a peptide hormone produced by the C cells of the thyroid gland. A disulfi de bond between positions 1 and 7 is essential for biologic activity. Calcitonin derived from fi sh has more potent antiresorptive effect than the human recombinant one and reduces bone resorption by inhibiting osteoclast activity and bone mass increase. In the study Prevent Recurrence of Osteoporotic Fractures (PROOF) was shown that a daily dose of 200 IU recombinant salmon nasal-calcitonin reduces vertebral fractures by 36%. Since July 2012, the European Medicines Agency (EMA) does not recommend its use for the treatment of osteoporosis due to increased frequency of certain types of cancers in the study PROOF. 46 It has been shown to increase bone mass and reduce fractures, but only in the spine. It does not appear to be as effective as bisphosphonates or teriparatide.
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)
Selective estrogen receptor modulators (SERMs) have been developed to retain the benefi cial effects of estrogens on bone while minimizing deleterious effects on breast, uterus, and the cardiovascular system. Tamoxifen was the fi rst SERM to be widely used in clinical practice, based on its now wellrecognized estrogen antagonist activity in the breast. The prolonged use of tamoxifen was associated with an increase in uterine cancer, leading to the search for other SERMs with different pharmacological profi les. 1, 4, 5 Thus raloxifene, bazedoxifene, lasofoxifene and arzoxifene, new SERMs, were developed for the treatment and prevention of postmenopausal osteoporosis, with the goal of improving the drug safety profi le. Raloxifene has a spectrum of tissue-specifi c agonist-antagonist effects on estrogen target tissues but acts on bone as an estrogen agonist. This drug has been extensively studied and data support its estrogen agonist profi le in the skeletal system. 47 The molecular mechanisms of action of SERM include: 1) differential binding activity to ER-α receptors (selective partial agonist / antagonist) and ER-β receptors (selective antagonist); 2) direct reduction of resorbing activity by inhibiting the production of interleukin 6, tumor necrosis factor α and inhibition of RANKL and increased production of transforming growth factor -β3. 47 SERM are shown for the prevention of vertebral fractures and treatment of osteoporosis in postmenopausal women. 47 
PHYTOESTROGENS
Phytoestrogens are polyphenolic plant metabolites: fl avonoids, fl avonols: kaempferol, quercetin, rutin, icariin; fl avanols: catechin, epicatechin of Camellia sinensis L.; polymeric fl avanols proanthocyanidins; fl avanones: hesperidin; isofl avones: daidzein, genistein, glycitein, kalita formononetin, biochanin A and coumestans, coumestrol, 4'-O-methylcoumestrol; isofl avones: equiol; polyphenols: oleuropein, oleocanthin; lignans: enterolactone, enterodiol; stilbenes: resveratrol. 48 Phytoestrogens possess estrogenic activity and show a higher affi nity for β-estrogen receptor, due to structural similarity with 17β-oestradiol stimulate osteoblast differentiation and inhibiting osteoclastogenesis. Rutin inhibits osteoclast formation by reducing the free radicals and the levels of TNF-α. 48 Isofl avones reduce the number of osteoclasts leads to restoring the balance between bone formation and resorption. Formononetin of Trifolium pratense antioxidant preventing bone resorption due to an increase in the activity of superoxide dismutase, catalase and glutathione peroxidase. Coumestrol increased alkaline phosphatase, type I collagen and osteocalcin activity and prevent bone resorption. Polyphenols such as oleuropein and oleocanthin stimulate osteoblasts and inhibit osteoclast formation. Lignan precursors lariciresinol, matairesinol, pinoresinol and secoisolariciresinol under the action 188 (1-34) , antagonists of the calcium-sensing receptors in the parathyroid gland (stimulate endogenous PTH secretion). The effects of PTH on bone vary greatly depending on the dose. At high levels of PTH (1-84) exhibits catabolic effect and primary hyperparathyroidism and fractures. Administration of low doses of PTH (1-84) or a fragment 1-34 (teraparatide) has an anabolic effect and stimulate bone formation by activation of the production of insulin-like factor 1, which facilitates the differentiation to osteoblasts and protects osteoblasts from apoptosis. PTH increases bone mineral content at the spine in men and women with glucocorticoid-induced osteoporosis. 49 PTH (1-84) in daily subcutaneous injection of 100 μg is effective in preventing a vertebral fracture (reduction of 40-50%) in postmenopausal women with severe osteoporosis. 49 Due to the strong stimulating effect on the osteoblasts teriparatide 20 μg subcutaneous is registered for use up to 18-24 months in: 1) men and women over 65 years with T-score ≤ -2.5 SD, as a fi rst line treatment alternative to bisphosphonates; 2) prevention of vertebral and non-vertebral fractures in postmenopausal women with low mineral density in severe osteoporosis T-score ≤ -3.5 SD and multiple vertebral fractures; 3) new fractures, increased rate of bone loss; 4) intolerant to other bone-active medicaments; 5) antiresorptive therapy ineffective; 6) the treatment of glucocorticoid-induced osteoporosis in men and women. The study EUROFORS in women with previous vertebral fracture reduction is achieved the risk of new vertebral fractures by 65% and the risk of non-vertebral fractures was reduced by 55%. 49 STRONTIUM RANELATE Strontium ranelate dissociates to non-radioactive trace element strontium, and ranelic acid that no pharmacological activity and is excreted unchanged by the kidney. 1, 4, 5 Evolved strontium affect bone metabolism and improves fracture. 5 Preclinical studies indicate that Strontium ranelate has a dual mechanism of action: 1) the stimulation of bone formation by: a) synthesis of bone collagen, alkaline phosphatase and osteocalcin; b) contacting a Ca-sensitive receptors that stimulate the mitogen-activated protein kinase enhancing the osteoblast differentiation and proliferation; 2) inhibition of osteoclastogenesis by inhibiting the differentiation, activity and life of osteoclasts; reduction of the expression of RANKL and increased expression in osteoblasts osteoprotegrin. The drug is administered as a fi rst line treatment of postmenopausal women and men with established osteoporosis who are at high risk for fracture. Preventing both vertebral and non-vertebral fractures and hip fractures. Large clinical trials have demonstrated its efficacy in increasing bone mineral density and decreasing fractures in the spine and hip. Performance data from clinical trials are: SOTI, TROPOS, PREVOS, STRATOS. 50 SOTI study proves that for 3 years strontium ranelate reduces the incidence of new vertebral fractures by 38% and the occurrence of vertebral and non-vertebral fractures -32%. However, European Pharmacovigilance Risk Assessment Committee (PRAC) recommends restriction in the use of strontium ranelate, based on a routine benefi t-risk assessment of the medicine, which included data showing an increased risk of heart problems, including heart attacks. 50 On January 10, 2014 PRAC has recommended that strontium ranelate should no longer be used to treat osteoporosis. 50 
COMBINATION THERAPY OF OSTEOPOROSIS
Option in the treatment of osteoporosis can be combination of anti-osteoporosis drugs of different classes. After a course of bisphosphonates the therapy could be continued with denosumab, PTH or strontium ranelate. 6, 7 Combination therapy showed greater reduction of fractures than single agent. 3 The use of a bisphosphonate in association with HRT has additive effects on the reduction of bone resorption markers and BMD. 6, 39 The administration of a bisphosphonate with raloxifene showed greater improvement in BMD. 39 Combination therapy with estrogen and testosteron leads to a signifi cantly higher bone density compared with estrogen monotherapy. 45 Bazedoxifene (20 mg / day) in combination with estrogens (0.625 mg / day) enhances bone density of the spine. 43 It has been shown to reduce the risk of fracture after administration of PTH / teriparatide. 49 
CONCLUSIONS
Combination of non-pharmacological and pharmacological treatment options have to be considered for prevention of osteoporosis and minimization of the risk of fractures. Given the heterogeneity of osteoporosis syndrome and lack of signifi cant comparative studies, the choice of a pharmacological agent should be individualized depending on the combination of several factors: 1) the profi le of the disease (severity of bone loss and risk factors); 2) the profi le of the patient (age, general health, underlying disease); 3) effi ciency (types and sizes of anti-fracture effect); 4) tolerance (side effects and contraindications associated); 5) accompanying diseases and contraindications.
